Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15659008 | 0.87 | USP2 (0.33) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL27751416 | 0.83 | USP2 (0.36) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL2025590 | 0.83 | USP2 (0.36) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL27751414 | 0.83 | USP2 (0.36) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL27825292 | 0.79 | USP2 (0.38) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL27655243 | 0.79 | USP2 (0.38) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL3467337 | 0.77 | USP2 (0.34) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL4587134 | 0.75 | USP2 (0.39) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL6247036 | 0.73 | USP2 (0.39) | USP2SLCO1B1PDE4ALMNAL3MBTL1 | |
| SCHEMBL8057556 | 0.72 | LMNA (0.48) | USP2SLCO1B1PDE4ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2911699-B2 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX BV (NL) | 2025-09-10 | — | — | EP | disclosed |
| US-20250177554-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX B.V. (NL) | 2025-06-05 | — | — | US | disclosed |
| US-12194107-B2 | Modified antibody, antibody-conjugate and process for the preparation thereof | SYNAFFIX B.V. (NL) | 2025-01-14 | — | — | US | disclosed |
| US-20230127659-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | SYNAFFIX B.V. (NL) | 2023-04-27 | — | — | US | disclosed |
| US-11590239-B2 | Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates | SYNAFFIX B.V. (NL) | 2023-02-28 | — | — | US | disclosed |
| EP-3057618-B1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SYNAFFIX BV (NL) | 2022-12-14 | — | — | EP | disclosed |
| US-11338043-B2 | Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates | SYNAFFIX B.V. (NL) | 2022-05-24 | — | — | US | disclosed |
| EP-3929301-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SynAffix B.V. (NL) | 2021-12-29 | — | — | EP | disclosed |
| EP-3912642-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | Synaffix B.V. (NL) | 2021-11-24 | — | — | EP | disclosed |
| EP-2935611-B1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SYNAFFIX BV (NL) | 2021-07-07 | — | — | EP | disclosed |
| US-9987373-B2 | Modified glycoprotein, protein-conjugate and process for the preparation thereof | SYNAFFIX B.V. (NL) | 2018-06-05 | — | — | US | disclosed |
| EP-3058083-B1 | MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX BV (NL) | 2018-04-11 | — | — | EP | disclosed |
| EP-2911699-B1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX BV (NL) | 2017-11-15 | — | — | EP | disclosed |
| WO-2017137458-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING CD30 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | SYNAFFIX B.V. (NL) | 2017-08-17 | — | — | WO | disclosed |
| US-9504758-B2 | Modified antibody, antibody-conjugate and process for the preparation thereof | SYNAFFIX B.V. (NL) | 2016-11-29 | — | — | US | disclosed |
| US-20160257764-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SYNAFFIX B.V. (NL) | 2016-09-08 | — | — | US | disclosed |
| US-20160250347-A1 | MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX B.V. (NL) | 2016-09-01 | — | — | US | disclosed |
| US-20160235861-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | SynAffix. B.V. (NL) | 2016-08-18 | — | — | US | disclosed |
| US-20150320882-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX B.V. (NL) | 2015-11-12 | — | — | US | disclosed |
| US-20150258210-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX B.V. (NL) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257764-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | FUT5, FCGR1A, FCGR3B | USP2 2630/4885SLCO1B1 2060/4885PDE4A 4743/4885 |
| US-20160235861-A1 | GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION | FCGR1A, FCGR3B, FCGR2A | USP2 2765/4885SLCO1B1 1795/4885PDE4A 4701/4885 |
| US-20150320882-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | FUT5, FUT6, FUCA1 | USP2 4081/4885SLCO1B1 1714/4885PDE4A 4685/4885 |
| US-20160250347-A1 | MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | FUT5, FUCA2, FUT4 | USP2 699/4885SLCO1B1 159/4885PDE4A 4438/4885 |
| US-11590239-B2 | Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates | FUT4, FUT5, FUT6 | USP2 4679/4885SLCO1B1 360/4885PDE4A 4812/4885 |
| US-12194107-B2 | Modified antibody, antibody-conjugate and process for the preparation thereof | FUT5, FUT6, FUT4 | USP2 3316/4885SLCO1B1 2007/4885PDE4A 4754/4885 |
| US-20150258210-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | FUT5, FUT6, FUT4 | USP2 3274/4885SLCO1B1 1827/4885PDE4A 4751/4885 |
| US-20250177554-A1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | FUT5, FUT6, FUT4 | USP2 3316/4885SLCO1B1 2007/4885PDE4A 4754/4885 |
| US-11338043-B2 | Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates | FUT6, FUT5, FUT4 | USP2 4225/4885SLCO1B1 460/4885PDE4A 4869/4885 |
| US-20230127659-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | FUT6, FUT5, FUT4 | USP2 4247/4885SLCO1B1 433/4885PDE4A 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.